Jobs with Puma Biotechnology
Puma Biotechnology, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces New Updates And Changes In Breast Cancer Treatment
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
PumaBiotech (@pumabiotech) / Twitter
Henry Kuo - Head of Information Technology - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology, Inc. 2020 Current Report 8-K
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
PumaBiotech (@pumabiotech) / Twitter
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology Is Soaring Today | Nasdaq
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting
Puma Biotechnology
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology, Inc. | LinkedIn
Exhibitor Puma Biotechnology 07-10 - Scripps CME Connection
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology says its breast cancer therapy included in two key NCCN updates | Seeking Alpha
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
